Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR8 | P51685 | 17/20 | 0.57 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.45 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1338776 | 0.87 | CCR8 (0.59) | CCR8TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL1339809 | 0.87 | CCR8 (0.58) | CCR8 | |
| SCHEMBL12129694 | 0.86 | CCR8 (0.53) | CCR8 | |
| SCHEMBL1337653 | 0.86 | CCR8 (0.72) | CCR8 | |
| SCHEMBL1340095 | 0.83 | CCR8 (0.74) | CCR8 | |
| SCHEMBL1337739 | 0.83 | CCR8 (0.49) | CCR8TAS1R3TAS1R1TAS1R2 | |
| Hydrochloric Acid SCHEMBL1337821 | 0.82 | CCR8 (0.48) | CCR8TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL1341331 | 0.80 | CCR8 (0.56) | CCR8 | |
| SCHEMBL1341325 | 0.79 | CCR8 (0.68) | CCR8 | |
| SCHEMBL1339686 | 0.79 | CCR8 (0.79) | CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063222-B2 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063222-B2 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063222-B2 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20090275556-A1 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | MILLENNIUM PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090275556-A1 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | MILLENNIUM PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090275556-A1 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | MILLENNIUM PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7491827-B2 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7491827-B2 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7491827-B2 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7378525-B2 | CCR8 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378525-B2 | CCR8 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378525-B2 | CCR8 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-05-27 | — | — | US | disclosed |
| EP-1590327-A1 | CCR8 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20050085518-A1 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | MILLENNIUM PHARMACEUTICALS, INC. | 2005-04-21 | — | — | US | disclosed |
| US-20040209948-A1 | CCR8 Inhibitors | MILLENNIUM PHARMACEUTICALS, INC. | 2004-10-21 | — | — | US | disclosed |
| WO-2004058709-A1 | CCR8 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085518-A1 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | CCR8, CCR1, CCR3 | CCR8 1/4885TAS1R3 280/4885TAS1R1 209/4885 |
| US-20090275556-A1 | Aryl sulfonamides useful as inhibitors of chemokine receptor activity | CCR8, CCR1, CCR3 | CCR8 1/4885TAS1R3 367/4885TAS1R1 234/4885 |
| US-20040209948-A1 | CCR8 Inhibitors | CCR8, CCR1, CCR3 | CCR8 1/4885TAS1R3 835/4885TAS1R1 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.